Literature DB >> 8898745

A polymeric form of fibronectin has antimetastatic effects against multiple tumor types.

R Pasqualini1, S Bourdoulous, E Koivunen, V L Woods, E Ruoslahti.   

Abstract

Metastasis accounts for most deaths in cancer patients. Tumor cell adhesion to the extracellular matrix through integrins is thought to be a critical step in metastasis and a potential target for therapeutic intervention. We show here that treatment of human osteosarcoma, melanoma and carcinoma cells with a polymeric form of fibronectin (sFN), before inoculation into nude mice, prevented tumor formation. Intraperitoneally administered sFN significantly reduced lung colonization from intravenously injected tumor cells (experimental metastasis) and from subcutaneous tumors in nude mice (spontaneous metastasis). Treatment with sFN blocked cell spreading and migration in vitro suggesting a possible mechanism for the antimetastatic effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898745     DOI: 10.1038/nm1196-1197

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  30 in total

1.  Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.

Authors:  Z Lu; G Jiang; P Blume-Jensen; T Hunter
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity.

Authors:  Ming Yi; Takao Sakai; Reinhard Fassler; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

3.  The first type III repeat in fibronectin activates an inflammatory pathway in dermal fibroblasts.

Authors:  Ran You; Mingzhe Zheng; Paula J McKeown-Longo
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

4.  Type I collagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Cheryl Chalberg; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Regulation of p38 MAP kinase by anastellin is independent of anastellin's effect on matrix fibronectin.

Authors:  Ran You; R Matthew Klein; Mingzhe Zheng; Paula J McKeown-Longo
Journal:  Matrix Biol       Date:  2009-02-04       Impact factor: 11.583

6.  Structure and unfolding of the third type III domain from human fibronectin.

Authors:  Jessica M Stine; Yizhi Sun; Geoffrey Armstrong; Bruce E Bowler; Klára Briknarová
Journal:  Biochemistry       Date:  2015-10-30       Impact factor: 3.162

7.  VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail.

Authors:  Andrew J Evans; Ryan C Russell; Olga Roche; T Nadine Burry; Jason E Fish; Vinca W K Chow; William Y Kim; Arthy Saravanan; Mindy A Maynard; Michelle L Gervais; Roxana I Sufan; Andrew M Roberts; Leigh A Wilson; Mark Betten; Cindy Vandewalle; Geert Berx; Philip A Marsden; Meredith S Irwin; Bin T Teh; Michael A S Jewett; Michael Ohh
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

8.  A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis.

Authors:  M Yi; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

9.  Cryptic activity within the Type III1 domain of fibronectin regulates tissue inflammation and angiogenesis.

Authors:  Christina Cho; Rhiannon Kelsh-Lasher; Anthony Ambesi; Paula J McKeown-Longo
Journal:  Curr Top Pept Protein Res       Date:  2015

10.  A novel fibronectin binding motif in MSCRAMMs targets F3 modules.

Authors:  Sabitha Prabhakaran; Xiaowen Liang; Jonathan T Skare; Jennifer R Potts; Magnus Höök
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.